key: cord-0862208-dmob7dsc authors: Simon, D.; Tascilar, K.; Fagni, F.; Kleyer, A.; Kroenke, G.; Meder, C.; Dietrich, P.; Orlemann, T.; Moessner, J.; Taubmann, J.; Yalcin Mutlu, M.; Knitza, J.; Kemenes, S.; Liphardt, A. M.; Schoenau, V.; Bohr, D.; Schuster, L.; Hartmann, F.; Leppkes, M.; Ramming, A.; Pachowsky, M.; Schuch, F.; Ronneberger, M.; Kleinert, S.; Hueber, A. J.; Atreya, R.; Berking, C.; Sticherling, M.; Neurath, M. F.; Schett, G. title: Intensity and longevity of SARS-CoV-2 vaccination response and efficacy of adjusted vaccination schedules in patients with immune-mediated inflammatory disease date: 2022-04-12 journal: nan DOI: 10.1101/2022.04.11.22273729 sha: 9b704d4383d26d22acfb506bd467db0fd5f62981 doc_id: 862208 cord_uid: dmob7dsc Objectives To investigate the intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease (IMID) by diagnosis, treatment and adapted vaccination schedules. Methods SARS-CoV-2 IgG antibody response after SARS-CoV-2 vaccination was measured longitudinally in a large prospective cohort of healthy controls (HC) and IMID patients between December 2020 and 2021. Demographic and disease-specific data were recorded. Humoral response was compared across treatment and disease groups, and with respect to receipt of booster vaccinations. Age and sex adjusted SARS-CoV-2 antibody response was modelled over time. Marginal mean antibody levels and marginal risks of poor response were calculated at weekly intervals starting from week-8 after the first vaccination up to week 40. Results Among 5076 individuals registered, 2535 IMID patients and 1198 HC were eligible for this analysis. Mean antibody levels were higher in HC compared to IMIDs at all-time points, with peak antibody response in HC more than twice that in IMIDs (12.48 (11.52-13.52) vs. 5.71 (5.46-5.97)). Poor response to vaccination was observed in IMID patients treated with agents affecting B- and T-cell functions. Mean differences in antibody response between IMID diseases were small. After additional vaccinations, IMID patients could achieve higher antibody levels than HC vaccinated according to the two-dose schedule, even-though initial antibody levels were lower. Conclusions IMID patients show a lower and less durable SARS-CoV-2 vaccination response and are at risk to lose humoral immune protection. Adjusted vaccination schedules with earlier boosters and/or more frequent re-doses could better protect IMID patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a significant threat to patients with immune-mediated inflammatory diseases (IMIDs). Due to the immune dysfunction and use of immune-modulatory drugs, hosts responses to vaccination is altered in IMID patients and can vary considerably in terms of efficacy (1, 2) , longevity (3) , and protection against poor outcome (4) (5) (6) . From an immunological perspective, the majority of IMID patients are able to mount humoral immune responses after SARS-CoV-2 infection (7, 8) and vaccination (1, 2) . However, these responses appear to be blunted (1, 2) and the overall prevalence of anti-SARS-COV-2 antibody positivity due to infection is significantly lower compared to the general population (9) . This seems to be at least in part driven by specific immunomodulatory therapies such as methotrexate (10) , mycophenolate (11) , or rituximab (12) . As reports of waning vaccine efficacy and new virus variants resistant to antibody neutralization are emerging, increased susceptibility of IMID patients for earlier breakthrough infections are of particular concern (13). To date, the immunogenicity of SARS-CoV-2 vaccines in IMID patients has been studied mostly in the first two to six weeks after vaccination, whereas extended longitudinal data are scarce. One report suggested a more pronounced decline of humoral response to vaccination in IMID patients than in healthy subjects (14) . Considering that the levels of anti-SARS-CoV-2 IgG correlate with COVID-19 risk and vaccine efficacy (15) , this may represent a warning signal for waning immunity, especially in high-risk subsets of patients. Therefore, the question arises whether IMID patients could benefit from adjusted vaccination schedules, with more frequent booster vaccinations. To investigate the impact of treatment and vaccination strategies on longevity of humoral response in IMID patients and to provide evidence for current vaccination regimens of IMID patients, we analyzed a large prospective cohort of IMID patients and control subjects from the time on after the first SARS-CoV-2 vaccination. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint IMID patients and healthy controls (HC) were recruited from the prospective COVID-19 study program conducted by the Deutsche Zentrum fuer Immuntherapie, which since February 2020 has collected data on respiratory infections including COVID-19 as well as anti-SARS-CoV-2 antibody responses before and after the vaccination era and exposure risk behavior over time. Further study details have been described elsewhere (11) . Briefly, patients attending or admitted to affiliated centers who received either no treatment or treatment with immunomodulatory agents were recruited. HC included employees of the University Hospital Erlangen, and community-dwelling individuals recruited in several organized field campaigns during the pandemic (February/April 2020; December 2020/January 2021; November/December 2021). IMID patients were asked to participate during their routine follow-up visits. A structured questionnaire was used to collect data on demographic characteristics and comorbidities. The study was approved by the Institutional Review Board of Erlangen University Hospital (#157_20 B), and written informed consent was obtained from all study participants. Cohort participants with physician-diagnosed IMIDs including systemic autoimmune diseases, rheumatoid arthritis, spondyloarthritides (including psoriatic arthritis), vasculitides (excluding cutaneous-limited vasculitis), psoriasis, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), polymyalgia rheumatica and miscellaneous IMIDs including sarcoidosis, IgG-4 related fibrosing disease, juvenile idiopathic arthritis, myositis, autoinflammatory syndromes, inflammatory demyelinating diseases and control participants with no diagnosis of IMIDs were eligible for this analysis. Participants who were sampled while being evaluated for a possible IMID but remained without a clear diagnosis, those with organ specific autoimmunity (autoimmune thyroiditis, autoimmune liver disease), atopy (urticaria, asthma, atopic dermatitis), immunodeficiency, malignancy and those with uncertain diagnostic status were excluded. Included participants should have had at least one blood sample available starting from 4 weeks before their first vaccination date. Follow-up started at the time of first vaccination and continued until 01.12.2021. Samples were collected during routine visits for IMID patients, in response to email reminders for participating healthcare personnel and via several field campaigns by investigators for community-dwelling HC throughout the post-vaccination period. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint We categorized current immunomodulatory treatments used for IMIDs at each sampling timepoint as cytokine-(TNF-alpha, IL-1, IL-5, IL-6, IL-12/23, IL-17, IL- hydroxychloroquine, sulfasalazine) as detailed in Suppl. Table- 1. When a patient was on multiple concomitant treatments, this was indicated as a combination treatment in a separate variable and the assignment followed a hierarchy of priority such that: biological agents> signaling inhibitors > conventional immune modulators > other drugs > glucocorticoids. IgG antibodies against the S1 domain of the spike protein of SARS-CoV-2 were tested by the recent CE version (April 2020) of the commercial enzyme-linked immunosorbent assay from We used descriptive statistics to summarize cohort characteristics. Optical density values representing antibody levels were binned into 2-to 8-week intervals of sample acquisition time after the first vaccination for description and summarized as geometric means and standard deviations as observed. The time course of SARS-CoV2 antibody levels were analyzed after log-transformation and modelled as a function of time after the first vaccination using mixed effects linear regression. We also modelled marginal risks of poor response using mixed-effects logistic regression, where OD values <1.1 indicated poor response. As the relationship between time and antibody levels is expected to be curvilinear, we used restricted cubic splines with four degrees of freedom for time in all analyses. All models included age and sex at the time of first vaccination for adjustment, interaction terms between time and grouping variables and participant id as a random effect. We constructed three linear models to compare i) HC vs. all All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint IMID patients indicated by a binary variable, ii) HC and IMID diagnoses indicated by a categorical variable, iii) HC and dominant IMID treatments classified by primary mode of action. Using these models, we estimated age and sex-adjusted marginal geometric mean antibody levels at weekly intervals starting from week-8 after the first vaccination up to week 40. We performed pairwise between-group comparisons at the time of peak antibody response and at week 40 and calculated adjusted mean differences with 95% confidence intervals (CI) corrected for multiplicity by Tukey's method. All analyses were conducted using R v 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria) using packages lme4 and emmeans. Among 5076 individuals registered in our cohort, 3733 participants were eligible for this analysis including 2535 IMID patients and 1198 HC who provided overall 5564 samples between 15/12/2020 and 01/12/2021. A flow chart describing cohort assembly is depicted in Observed geometric mean SARS-CoV-2 IgG antibody levels by periods of follow-up after first vaccination are presented in Table- 2A. Largest OD values were observed in the 8-to 10- week period after vaccination in both groups, which seemed to be attained earlier in HC compared to IMID patients and with higher mean values. Estimated marginal mean antibody levels after adjustment for age and sex (Table-2B ) were higher in HC compared to IMIDs at all timepoints after 8 weeks, where the peak marginal mean antibody response in HC (12.48; 95%CI 11.52 to 13.52) was more than twice the value estimated for IMID patients (5.71; 95%CI 5.46 to 5.97) showing a large mean difference of 6.98 (95% CI 5.93 to 8.04). At week 40, the difference was less pronounced with a marginal mean antibody level of 3.31 (95% CI All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint 3.01 to 3.64) in HC compared to 2.40 (95% CI 2.00 to 2.88) in IMID patients, still with a small but significant mean difference of 0.91 (95% CI 0.37 to 1.44). HC showed a biphasic loss of antibodies over time; an initial rapid decline after the peak up to week 20 and a slower decline thereafter until week 40 as opposed to a relatively monophasic loglinear decline after a shallower peak in IMID patients (Figure-1A) . Observed proportion of samples showing poor antibody response (OD<1.1) ranged between 0 to 2.32% among HC, and 7.4% to 17.8% among IMID patients, rising steadily after the 8-to 10-week period ( Table-2A ). Average estimated marginal risk of poor-response at mean cohort age was higher in IMID patients compared to HC at all timepoints (Figure-1B) . These ranged between 0.25% to 2.88% in HC but was above 5% at all time points in IMID patients, reaching 12.82% (95%CI 10.11% to 16.12%) at week 32 and 26.08% (15.71% to 40.03%) at week 40, almost 10 times the risk estimated for HC (2.88%; 95%CI 1.35% to 6.06%) ( Age and sex-adjusted marginal mean antibody levels by diagnosis showed an overall blunted peak immune response in IMID patients compared to HC (Suppl. Table-2A, Figure-2 ). Of note, peak responses were also lower in untreated IMID patients than in HC (Suppl. Table- 2B, Figure-2 ). Largest adjusted mean differences between HC and IMID diagnosis groups were observed around week 10 ranging between 5.62 (95%CI 2.74 to 8.49) for psoriasis and 8.68 (95%CI 6.73 to 10.64) for "other diagnoses". Lowest responses were found in patients with rheumatoid arthritis, vasculitis and "other diagnoses". Within IMID groups, marginal mean autoantibody levels at peak were significantly lower in vasculitis and "other diagnoses" in comparison to those with systemic autoimmune diseases, inflammatory bowel diseases, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint polymyalgia rheumatica, psoriasis and spondyloarthritis with marginal mean differences ranging between 1.57 (95%CI 0.00 to 3.15) and 2.88 (0.38 to 5.37). The peak marginal mean antibody levels for RA were significantly lower than only that of psoriasis among all IMID groups with a mean difference of 2.60 (95%CI 0.11 to 5.09). At week 40, the mean differences in antibody levels between HC and IMID groups were mostly small and imprecise except for RA with a mean difference of 1.49 (95%CI 0.37 to 2.61) and spondyloarthritis with a mean difference of 1.44 (95%CI 0.25 to 2.62). The overall course of marginal mean antibody levels was not different in untreated IMID patients from those treated with antimalarials or sulfasalazine ("other agents") or those treated with glucocorticoid monotherapy (mostly low doses) (Suppl. Table- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint When combination treatment status was added to the model, monotherapy with cytokine inhibitors, T cell inhibitors and conventional immune modulators was associated with higher mean antibody levels than combination therapy. This was most clearly observed with cytokine inhibitors, early in the time course after vaccination and up to 30 weeks. (Figure-S2 ). Overall 241 (6.5%) participants had a third vaccine (Table-1 This large prospective cohort study shows lower intensity and reduced longevity of the antibody response to two doses of SARS-CoV-2 vaccination in IMID patients. Peak response in IMID patients was less than half of that observed in HC after adjustment. Furthermore, IMID patients showed lower mean antibody levels over the entire course of follow-up losing humoral immunity more frequently. Of note, one fifth of younger and one third of older IMID patients lose humoral response 40 weeks after basal immunization. Our results also provide useful insights on the course of vaccine response across various treatment groups. They show particularly poor responses in patients treated with B-cell and T-cell inhibitors. Furthermore, while IMID patients treated with cytokine inhibitors showed peak responses comparable to untreated IMID patients, durability of response was not as good and fell beneath that of untreated IMID patients over time. To ensure sufficient protection, earlier administration of booster doses may be critical in IMID patients. We had previously shown that IMID patients who did not develop antibodies after two doses of SARS-Cov2 vaccination were likely to develop antibodies after a third dose (16) . In this study, we demonstrate that, after the booster, IMID patients could achieve anti-SARS-CoV-2 IgG levels higher than non-boosted HC, even though the initial mean antibody levels after the first two vaccinations were lower. In addition, given the observation that peak All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; 1 0 antibody levels at 10 weeks after the first vaccination in IMID patients are similar to 16-to 24-week levels in HC, it might be reasonable to administer the third dose within the three to four months of the first dose. Our study has some limitations. We have collected serum samples in an unscheduled timeline along the routine care of IMID patients, this may have resulted in more frequent or diligent sampling in IMID patients who get to visit the clinic more frequently. To mitigate this potential bias, we have used regression methods that account for within patient correlations using random effects. Samples from IMID patients were obtained predominantly under cytokine blocking treatments, therefore the overall between-group comparisons should reflect the weight of this treatment class, which affects the generalizability of our results. On the other hand, we also observe similar differences between IMID patients not receiving any immunomodulating treatment and HC. We did not attempt to separate the effects of treatments independent of diseases or antibody response across disease activity states, therefore the antibody levels reported here could be considered as average effects of treatments combined with the variety of diseases they are used for or similarly as average effects of diagnoses combined with their routine treatment patterns. We did not collect data on corticosteroid doses, however higher dosed corticosteroid treatments are usually given in combination with cytotoxic agents in conditions such as lupus nephritis or ANCA associated vasculitis. Therefore, their effects could be considered as embedded within those treatment categories and participants using only corticosteroid treatment should be more likely on lower maintenance doses, which may explain the relatively favorable antibody course with corticosteroids in comparison to cytotoxic or anti-cytokine treatments. In conclusion, these data support the concept that IMID patients are at risk to lose protective humoral response after basic SARS-CoV-2 vaccination, a phenomenon, which has also been observed after SARS-CoV-2 infection (3, 9) . Considering that anti-SARS-CoV-2 IgG are a good surrogate of protection against COVID-19 (17), lower overall antibody titers may also reflect a higher susceptibility to breakthrough infections. Hence adapted vaccination schedules that include earlier boosters should be implemented to more adequately protect IMID patients. We hope that these findings will be of use to policymakers responsible for disease control and prevention to reconsider current recommendations. Footnotes All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. None to declare Patient consent for data and publication Based on ethics approval #157_20 B and the TARDA database. Ethical approval (#157_20 B) to conduct this study was granted by the Institutional Review Board of the University Hospital Erlangen. Written informed consent was obtained from the study participants. All data relevant to the study are included in the article or uploaded as supplementary information. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. What is already known about this subject? While it is known that SARS-CoV-2 vaccination is effective in the general population, few data on the sustained efficacy of the vaccine in patients with immune-mediated inflammatory diseases (IMIDs) exist at the moment. Most importantly, it is not known whether the immune response against the SARS-CoV-2 vaccine is durable and how it is influenced by immunemodulatory therapy. The study shows that the antibody response of IMID patients after two doses of SARS-CoV-2 vaccination does not only have a lower intensity but also a reduced durability. Especially Our data support the introduction of adjusted vaccination schedules with more frequent booster vaccinations in IMID patients to ensure effective immunization to prevent breakthrough infections. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint Tables Table-1 Participant characteristics Group IMID Healthy controls All n=2535 n=1198 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. ; https://doi.org/10.1101/2022.04.11.22273729 doi: medRxiv preprint after first vaccination by IMID diagnoses. Bands indicate 95% confidence intervals. Panels ordered by 7 peak mean value. Other diagnoses include sarcoidosis, autoinflammatory diseases, IgG-4 disease, 8 inflammatory myopathy, juvenile idiopathic arthritis and inflammatory demyelinating diseases. and IMID patients receiving 2 vs 3 doses. Bands indicate 95% confidence intervals. 1 7 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 12, 2022. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses Immune-Mediated Inflammatory Diseases -Case Series from New York Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes antibody response after COVID-19 in patients with rheumatic disease Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immunemediated inflammatory disease High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection